As a leader in muscle biology research, we are dedicated to our mission of improving the lives of people confronting devastating diseases of impaired muscle function.
SOUTH SAN FRANCISCO, Calif., July 14, 2016 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq:CYTK) announced today that it is scheduled to report second quarter results on Thursday, July 28, 2016 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics’ senior management will host a conference call at 4:30 PM...READ MORE ›
People fighting amyotrophic lateral sclerosis have few treatment options; we are dedicated to changing the progression of this fatal disease.
Heart failure death and disability rates continue to rise, despite current treatment options. With Amgen, we are developing a novel therapy that may improve cardiac performance in people with heart failure.
People suffering from spinal muscular atrophy experience devastating loss of muscle function. With Astellas, we are working on a treatment that may enhance skeletal muscle performance in these and other patients.